 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"PHENYTOIN SODIUM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Withdrawal Precipitated Seizure : May precipitate status epilepticus. Dose reductions or discontinuation should be done [0m
[31mgradually. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Serious Dermatologic Reactions : Discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this [0m
[31mdrug should not be resumed and alternative therapy should be considered. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m hypersensitivity : If signs or symptoms of [0m
[31mhypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Hematopoietic Complications: If occurs, follow-up observation is [0m
[31mindicated and an alternative antiepileptic treatment should be used. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Cardiovascular Risk Associated with Rapid Infusion Rapid intravenous [0m
[31madministration of Phenytoin Sodium Injection increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Cardiac arrhythmias have included [0m
[31mbradycardia, heart block, ventricular tachycardia, and ventricular fibrillation which have resulted in asystole, cardiac arrest, and death. Severe complications are most commonly encountered in [0m
[31mcritically ill patients, elderly patients, and patients with hypotension and severe myocardial insufficiency. However, cardiac events have also been reported in adults and children without underlying [0m
[31mcardiac disease or comorbidities and at recommended doses and infusion rates. Intravenous administration should not exceed [0m[1;31m50[0m[31m mg per minute in adults. In pediatric patients, administer the drug at a [0m
[31mrate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower. PHENYTOIN SODIUM: warnings_and_cautions: Although the risk of cardiovascular toxicity increases with infusion rates above [0m
[31mthe recommended infusion rate, these events have also been reported at or below the recommended infusion rate. As non-emergency therapy, Phenytoin Sodium Injection should be administered more slowly [0m
[31mas either a loading dose or by intermittent infusion. Because of the risks of cardiac and local toxicity associated with intravenous phenytoin, oral phenytoin should be used whenever possible. Because[0m
[31madverse cardiovascular reactions have occurred during and after infusions, careful cardiac and respiratory monitoring is needed during and after the administration of intravenous Phenytoin Sodium [0m
[31mInjection. Reduction in rate of administration or discontinuation of dosing may be needed. [0m[1;31m5.2[0m[31m Withdrawal Precipitated Seizure, Status Epilepticus Antiepileptic drugs should not be abruptly [0m
[31mdiscontinued because of the possibility of increased seizure frequency, including status epilepticus. PHENYTOIN SODIUM: warnings_and_cautions: When, in the judgment of the clinician, the need for [0m
[31mdosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, this should be done gradually. However, in the event of an allergic or hypersensitivity reaction, [0m
[31mrapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an antiepileptic drug not belonging to the hydantoin chemical class. [0m[1;31m5.3[0m[31m Serious Dermatologic [0m
[31mReactions Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis [0m[1;31m([0m[31mTEN[0m[1;31m)[0m[31m and Stevens-Johnson syndrome [0m[1;31m([0m[31mSJS[0m[1;31m)[0m[31m, have been reported with phenytoin treatment. The onset of [0m
[31msymptoms is usually within [0m[1;31m28[0m[31m days, but can occur later. Phenytoin should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest [0m
[31mSJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. PHENYTOIN SODIUM: warnings_and_cautions: If a rash occurs, the patient should be evaluated for signs and [0m
[31msymptoms of Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m [0m[31m . Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the [0m
[31mpresence of HLA-B*[0m[1;31m1502[0m[31m, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*[0m[1;31m1502[0m[31m may be a risk factor for the development of SJS/TEN [0m
[31min patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. PHENYTOIN SODIUM: warnings_and_cautions: In addition, retrospective, case-control, [0m
[31mgenome-wide association studies in patients of southeast Asian ancestry have also identified an increased risk of SCARs in carriers of the decreased function CYP2C9*[0m[1;31m3[0m[31m variant, which has also been [0m
[31massociated with decreased clearance of phenytoin. Consider avoiding Phenytoin Sodium Injection as an alternative to carbamazepine in patients who are positive for HLA-B*[0m[1;31m1502[0m[31m or in CYP2C9*[0m[1;31m3[0m[31m carriers [0m[31m .[0m
[31mThe use of HLA-B*[0m[1;31m1502[0m[31m or CYP2C9 genotyping has important limitations and must never substitute for appropriate clinical vigilance and patient management. PHENYTOIN SODIUM: warnings_and_cautions: The [0m
[31mrole of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m dose, compliance, concomitant medications, comorbidities, and the level of [0m
[31mdermatologic monitoring have not been studied. [0m[1;31m5.4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms [0m
[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan Hypersensitivity, has been reported in patients taking antiepileptic drugs, including phenytoin. Some of these events have been fatal or life-threatening. DRESS [0m
[31mtypically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological[0m
[31mabnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. PHENYTOIN SODIUM: warnings_and_cautions: Because this disorder is variable in its [0m
[31mexpression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash[0m
[31mis not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin Sodium Injection should be discontinued if an alternative etiology for the signs or [0m
[31msymptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin hypersensitivity [0m[31m . Additionally, consider [0m
[31malternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., carbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and oxazolidinediones [0m[1;31m([0m[31me.g., trimethadione[0m[1;31m)[0m[31m in these same patients. PHENYTOIN SODIUM:[0m
[31mwarnings_and_cautions: Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in the patient or immediate family members, consider alternatives to [0m
[31mphenytoin. [0m[1;31m5.6[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events may be part of the spectrum of DRESS [0m
[31mor may occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin [0m
[31mhepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered. [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: [0m
[31mwarnings_and_cautions: [0m[1;31m7[0m[31m Hematopoietic Complications Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included [0m
[31mthrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have been a number of reports suggesting a relationship between [0m
[31mphenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a cause and effect [0m
[31mrelationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur[0m
[31mwith or without symptoms and signs resembling DRESS [0m[31m.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: boxed_warning: WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION The rate of intravenous Phenytoin Sodium Injection administration should not exceed [0m[1;31m50[0m[31m mg per [0m
[31mminute in adults and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is [0m
[31mneeded during and after administering intravenous Phenytoin Sodium Injection. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these [0m
[31mevents have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed [0m[31m . PHENYTOIN SODIUM: boxed_warning: W ARN ING: [0m
[31mCARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION S ee full prescribing information for complete boxed warning . The rate of intravenous Phenytoin Sodium Injection administration should not exceed [0m[1;31m50[0m
[31mmg per minute in adults and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac [0m
[31mmonitoring is needed during and after administering intravenous Phenytoin Sodium Injection. Reduction in rate of administration or discontinuation of dosing may be needed [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m , [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: openfda: spl_set_id         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse [0m
[31mdevelopmental outcomes. [0m[1;31m([0m[31m [0m[1;31m5.11[0m[31m , [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure [0m
[31mRegistry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as Phenytoin Sodium Injection, during pregnancy. Physicians are [0m
[31madvised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry. This can be done by calling the toll free number [0m
[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. PHENYTOIN SODIUM: use_in_specific_populations: Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. In addition, the fetal hydantoin syndrome a pattern of [0m
[31mabnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to [0m
[31mepileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in [0m
[31mchildren whose mothers received phenytoin during pregnancy. PHENYTOIN SODIUM: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal [0m
[31mmalformations and other manifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In [0m
[31mthe U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. The background risk of[0m
[31mmajor birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy [0m
[31mbecause of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage[0m
[31m. However, postpartum restoration of the original dosage will probably be indicated. PHENYTOIN SODIUM: use_in_specific_populations: Fetal/Neonatal adverse reactions A potentially life-threatening [0m
[31mbleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K [0m
[31madministration to the mother before delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an [0m
[31mapproximately [0m[1;31m2.4[0m[31m-fold increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital [0m
[31mhypoplasia has been reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and [0m
[31mneurodevelopmental deficiencies.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control [0m
[31musing alternative antiepileptic drugs. [0m[1;31m5.8[0m[31m Local Toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m Soft tissue irritation and inflammation has occurred at the site of injection with and without extravasation[0m
[31mof intravenous phenytoin. Edema, discoloration and pain distal to the site of injection [0m[1;31m([0m[31mdescribed as “purple glove syndrome”[0m[1;31m)[0m[31m have also been reported following peripheral intravenous phenytoin [0m
[31minjection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for several days after injection. Although resolution of symptoms [0m
[31mmay be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN SODIUM: [0m
[31mwarnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through a large-gauge [0m
[31mcatheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then be followed [0m
[31mby a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration may cause [0m
[31mpain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is[0m
[31mincreased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m5.10[0m[31m [0m
[31mExacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this [0m
[31mdisease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks [0m
[31mfor congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN SODIUM: warnings_and_cautions: Increased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac [0m
[31mdefects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and [0m
[31mcognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several [0m
[31mreported cases of malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns [0m
[31mexposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia [0m
[31mHyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN SODIUM: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic [0m
[31mpatients. [0m[1;31m5.13[0m[31m Serum Phenytoin Levels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m
[31m"encephalopathy"[0m[31m, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction [0m
[31mof phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Cardiovascular Risk Associated with Rapid Infusion [0m[31m [0m
[31mWithdrawal Precipitated Seizure, Status Epilepticus [0m[31m Serious Dermatologic Reactions [0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity [0m[31m Hypersensitivity [0m[31m [0m
[31mHepatic Injury [0m[31m Hematopoietic Complications [0m[31m Local toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m [0m[31m Exacerbation of Porphyria [0m[31m Teratogenicity and Other Harm to the Newborn [0m[31m Hyperglycemia [0m[31m The following [0m
[31madverse reactions associated with the use of Phenytoin Sodium Injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population[0m
[31mof uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most notable signs of toxicity associated with the [0m
[31mintravenous use of this drug are cardiovascular collapse and/or CNS depression. Hypotension does occur when the drug is administered rapidly by the intravenous route. PHENYTOIN SODIUM: [0m
[31madverse_reactions: The rate of administration is very important; it should not exceed [0m[1;31m50[0m[31m mg per minute in adults, and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients [0m
[31m. Body As a Whole: Allergic reactions in the form of rash and rarely more serious forms [0m[1;31m([0m[31msee Skin and Appendages paragraph below[0m[1;31m)[0m[31m and DRESS [0m[31m have been observed. Anaphylaxis has also been reported. [0m
[31mThere have also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe cardiovascular events and [0m
[31mfatalities have been reported with atrial and ventricular conduction depression and ventricular fibrillation. PHENYTOIN SODIUM: adverse_reactions: Severe complications are most commonly encountered in[0m
[31melderly or critically ill patients [0m[31m . Digestive System: Acute hepatic failure [0m[31m , toxic hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. [0m
[31mHematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin [0m[31m . These have included thrombocytopenia, [0m
[31mleukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to [0m
[31mfolic acid therapy.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available documentation does not explicitly mention an increased or decreased risk of angioedema associated with PHENYTOIN SODIUM. However, PHENYTOIN SODIUM does have warnings about [0m
[32mserious dermatologic reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;32m([0m[32mDRESS[0m[1;32m)[0m[32m/[0m[32mMultiorgan[0m[32m hypersensitivity, which can present with rash, fever, lymphadenopathy, and/or facial [0m
[32mswelling, along with other organ system involvement. These reactions can be severe and sometimes fatal. If such signs or symptoms are present, immediate evaluation is recommended, and PHENYTOIN SODIUM[0m
[32mshould be discontinued if an alternative etiology for the signs or symptoms cannot be established.[0m

[32mSOURCE: PHENYTOIN SODIUM label[0m
[32mEXTRACT_START_END: Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;32m([0m[32mDRESS[0m[1;32m)[0m[32m...[0m[32mshould be discontinued if an[0m[32m...[0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available documentation does not explicitly mention an [0m
[34mincreased or decreased risk of angioedema associated with PHENYTOIN SODIUM. However, PHENYTOIN SODIUM does have warnings about serious dermatologic reactions, including Drug Reaction with Eosinophilia[0m
[34mand Systemic Symptoms [0m[1;34m([0m[34mDRESS[0m[1;34m)[0m[34m/[0m[34mMultiorgan[0m[34m hypersensitivity, which can present with rash, fever, lymphadenopathy, and/or facial swelling, along with other organ system involvement. These reactions can [0m
[34mbe severe and sometimes fatal. If such signs or symptoms are present, immediate evaluation is recommended, and PHENYTOIN SODIUM should be discontinued if an alternative etiology for the signs or [0m
[34msymptoms cannot be established.[0m

[34mSOURCE: PHENYTOIN SODIUM label[0m
[34mEXTRACT_START_END: Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;34m([0m[34mDRESS[0m[1;34m)[0m[34m...[0m[34mshould be discontinued if an[0m[34m...[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for PHENYTOIN SODIUM does not explicitly mention an [0m
[32mincreased or decreased risk of angioedema. However, it does warn about serious dermatologic reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;32m([0m[32mDRESS[0m[1;32m)[0m[32m/[0m[32mMultiorgan[0m[32m [0m
[32mhypersensitivity, which can present with symptoms such as rash, fever, lymphadenopathy, and/or facial swelling, along with other organ system involvement. These reactions can be severe and sometimes [0m
[32mfatal, and if such signs or symptoms are present, immediate evaluation is recommended. PHENYTOIN SODIUM should be discontinued if an alternative etiology for the signs or symptoms cannot be [0m
[32mestablished.[0m

[32mGiven this information, while angioedema is not specifically mentioned, the warning about facial swelling as part of a hypersensitivity reaction suggests that there may be a potential risk for [0m
[32mangioedema, as it is a form of swelling that can occur in similar hypersensitivity reactions. However, without explicit mention of angioedema in the label, we cannot definitively say that PHENYTOIN [0m
[32mSODIUM increases the risk of angioedema based on the FDA label data alone.[0m

[32mTherefore, the degree of reliability of this answer is limited to the information provided in the FDA label, which does not confirm a direct association between PHENYTOIN SODIUM and angioedema.[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the FDA label for PHENYTOIN SODIUM does not explicitly mention an increased or decreased risk of angioedema. However, it does warn about serious dermatologic [0m
[32mreactions, including Drug Reaction with Eosinophilia and Systemic Symptoms [0m[32m([0m[32mDRESS[0m[32m)[0m[32m/Multiorgan hypersensitivity, which can present with symptoms such as rash, fever, lymphadenopathy, and/or facial [0m
[32mswelling."[0m[32m,[0m
[32m      [0m[32m"Based on the information provided, while angioedema is not specifically mentioned, the warning about facial swelling as part of a hypersensitivity reaction suggests that there may be a [0m
[32mpotential risk for angioedema, as it is a form of swelling that can occur in similar hypersensitivity reactions."[0m[32m,[0m
[32m      [0m[32m"Without explicit mention of angioedema in the label, we cannot definitively say that PHENYTOIN SODIUM increases the risk of angioedema based on the FDA label data alone."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for PHENYTOIN SODIUM does not explicitly state that it increases or decreases the risk of angioedema. Therefore, based on the FDA label data, we do not know if PHENYTOIN [0m
[32mSODIUM has an effect on the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN SODIUM increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the FDA label for PHENYTOIN SODIUM does not explicitly mention an increased or decreased risk of angioedema. However, it does warn about serious dermatologic [0m
[34mreactions, including Drug Reaction with Eosinophilia and Systemic Symptoms [0m[34m([0m[34mDRESS[0m[34m)[0m[34m/Multiorgan hypersensitivity, which can present with symptoms such as rash, fever, lymphadenopathy, and/or facial [0m
[34mswelling."[0m[34m,[0m
[34m      [0m[34m"Based on the information provided, while angioedema is not specifically mentioned, the warning about facial swelling as part of a hypersensitivity reaction suggests that there may be a [0m
[34mpotential risk for angioedema, as it is a form of swelling that can occur in similar hypersensitivity reactions."[0m[34m,[0m
[34m      [0m[34m"Without explicit mention of angioedema in the label, we cannot definitively say that PHENYTOIN SODIUM increases the risk of angioedema based on the FDA label data alone."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for PHENYTOIN SODIUM does not explicitly state that it increases or decreases the risk of angioedema. Therefore, based on the FDA label data, we do not know if PHENYTOIN [0m
[34mSODIUM has an effect on the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN SODIUM increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the FDA label for PHENYTOIN SODIUM does not explicitly mention an increased or decreased risk of angioedema. However, it does warn about serious dermatologic reactions, [0m
[31mincluding Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m hypersensitivity, which can present with symptoms such as rash, fever, lymphadenopathy, and/or facial swelling.[0m
[1;31m3[0m[31m. Based on the information provided, while angioedema is not specifically mentioned, the warning about facial swelling as part of a hypersensitivity reaction suggests that there may be a potential [0m
[31mrisk for angioedema, as it is a form of swelling that can occur in similar hypersensitivity reactions.[0m
[1;31m4[0m[31m. Without explicit mention of angioedema in the label, we cannot definitively say that PHENYTOIN SODIUM increases the risk of angioedema based on the FDA label data alone.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for PHENYTOIN SODIUM does not explicitly state that it increases or decreases the risk of angioedema. Therefore, based on the FDA label data, we do not know if [0m
[31mPHENYTOIN SODIUM has an effect on the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for PHENYTOIN SODIUM does not explicitly state that it increases or decreases the risk of angioedema. Therefore, based on the FDA label data, we do not know if PHENYTOIN SODIUM has an [0m
[32meffect on the risk of angioedema.[0m
